Clinical infrastructure · English + Español

One record. Every practice.Only the care travels.

Mendarion gives each person one master record and gives each practice only what a live grant allows. Check-ins, scheduling, encounters, documents and prescribing sit on one auditable spine — in English and Spanish.

Create your account Browse the directory

Three data planes, separated by construction
Cross-plane reads only through a scoped, revocable grant
Every action attributed; every read in the access log

The whole loop

Built for the work between visits

The person owns the file

Demographics, conditions, allergies and medications live in the person's own store. A practice reads only the sections a grant covers, and revocation stops the next request — not the next day.

The practice runs its day

Calendar, check-ins, encounters, documents and prescriptions on one rail — with a practice owner, roles, and an activity trail that names the actor.

AI that stays advisory

Triage runs on redacted text, asynchronously, with the model and prompt recorded. A suggestion never writes itself into the record — a professional decides.

The daily brief

Medicine, without the noise

The health-desk stories that moved today, refreshed every morning. Every headline links to its publisher.

Updated Nov 10, 11:52 PMHeadlines via heraldfox.com All stories

MedPage TodayNov 10, 8:22 PM
Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval
The FDA approved the small-molecule inhibitor pimicotinib (Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) and high surgical risk. An oral selective inhibitor of colony stimulating factor...
- Clinical Practice
- Pharma & Biotech
Read at the publisher

Bring your practice online this week

Start with a directory listing, then run the day from one rail. This demo is synthetic: no real patient records, no AI vendor calls.

Create your account See who is already listed

MedPage Today

Nov 10, 4:10 PM

New Medicare Payment Model for Back Pain, Heart Failure Riles Docs

Physician groups are seeking a delay for a new Medicare demonstration model. The model debuts January 1 and requires doctors treating low back pain and congestive heart failure to meet performance standards or face payment penalties. That means those physicians could see payment consequences tied to the standards if the model starts on schedule.

Clinical Practice
Public Health

Read at the publisher

Heather LandiNov 10, 8:51 PM

Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs

Hims & Hers struck a deal with Eli Lilly to offer the drugmaker’s branded obesity treatments through its online health and wellness platform.

Clinical Practice
Pharma & Biotech

Read at the publisher

Heather LandiNov 10, 8:51 PM

Doximity expands clinical AI footprint to more than 190 health systems

Doximity is expanding its clinical AI footprint to more than 190 health systems. The company is also positioning clinical reliability as a competitive focus, launching DoseCheck and a partnership with Wolters Kluwer's UpToDate.

Clinical Practice
Hospitals & Systems

Read at the publisher

MedPage TodayNov 10, 5:03 PM

Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B

Reductions in hepatitis B surface antigen (HBsAg) were observed with a novel small interfering RNA (siRNA) therapy in patients with chronic hepatitis B virus (HBV) infection, according to a phase II study. Among patients randomized...

Clinical Practice
Pharma & Biotech

Read at the publisher

Cailey GleesonNov 10, 8:51 PM

Mayo Clinic Platform launches AI-driven clinical decision support tool

Mayo Clinic Platform launched an AI-driven clinical decision support tool. Beginning in November, eligible clinicians will get a specialty-specific chat covering more than 35 specialties plus 22 clinical calculators available via chat or voice dictation.

Clinical Practice

Read at the publisher

MedPage TodayNov 10, 3:31 PM

Novel ADC Boosts Survival in Pretreated Endometrial Cancer

Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...

Clinical Practice
Pharma & Biotech

Read at the publisher

MedPage TodayNov 10, 6:15 PM

Cutaneous Sarcoidosis Could Soon Get an Effective Therapy

Brepocitinib produced dramatic improvement in patients with cutaneous sarcoidosis, a condition lacking any very effective therapy, in a small phase II trial presented in Orlando. The dual-acting TYK2/JAK1 inhibitor, marketed as Lisraya, was tested in a trial the excerpt describes only as small, without giving a patient count or effect size.

Clinical Practice
Pharma & Biotech

Read at the publisher

Loading…

One record. Every practice.Only the care travels.

Built for the work between visits

The person owns the file

The practice runs its day

AI that stays advisory

Medicine, without the noise

Bring your practice online this week